Sign In
Buy KPTI
$9.00
-0.230 (-2.49%)
At Close: Jun 03, 2026
7 ans de prison pour inceste avec séquestration sur sa demi-soeur
11:46am, Tuesday, 30'th Jun 2020
Il a imposé une relation sexuelle de force, avec violence, menace et séquestration à la victime
Top Small Cap Stocks for July 2020
04:53pm, Monday, 29'th Jun 2020
Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a sh
Rhythm's Setmelanotide Data And Other News: The Good, Bad And Ugly Of Biopharma
02:23am, Sunday, 28'th Jun 2020
Rhythm reports positive Setmelanotide data. Biohaven’s Troriluzole flops in late stage study. Karyopharm's XPOVIO receives approval.
Analysts Offer Insights on Healthcare Companies: Dynavax (NASDAQ: DVAX) and BELLUS Health (NASDAQ: BLU) - Markets
10:26am, Friday, 26'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dynavax (DVAX
Analysts Offer Insights on Healthcare Companies: Chimerix (NASDAQ: CMRX) and BerGenBio AS (Other OTC: BRRGF) - Markets
10:19am, Friday, 26'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chimerix (CMRX
2020 Insights into the Global Multiple Myeloma Market and Competitive Landscape - ResearchAndMarkets.com
12:00am, Friday, 26'th Jun 2020
The
Pedidos de seguro-desemprego sobem 35% na 1ª quinzena de junho e somam 3,6 milhões em 2020
11:28pm, Thursday, 25'th Jun 2020
Levantamento foi divulgado hoje pela Secretaria de Trabalho
Brokers Issue Forecasts for Karyopharm Therapeutics Inc’s Q2 2020 Earnings (NASDAQ:KPTI)
08:38am, Thursday, 25'th Jun 2020
Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Equities researchers at SVB Leerink lifted their Q2 2020 EPS estimates for shares of Karyopharm Therapeutics in a research note issued on Monday, June 22n
HC Wainwright Increases Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $41.00
08:06am, Thursday, 25'th Jun 2020
Karyopharm Therapeutics (NASDAQ:KPTI) had its target price hoisted by HC Wainwright from $40.00 to $41.00 in a research report issued on Tuesday, BenzingaRatingsTable reports. The brokerage presently
XPOVIO® (selinexor) Now Approved for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Available from Onco360
06:01pm, Wednesday, 24'th Jun 2020Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology
11:00am, Wednesday, 24'th Jun 2020
Karyopharm Therapeutics Inc. (KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluatin
Karyopharm Stock Down From Peak Despite Commercial Progress And Strong Data Provides Investor Opportunity
09:48am, Wednesday, 24'th Jun 2020
Xpovio is anticipated to become a blockbuster multiple myeloma MM treatment, and real-world data demonstrate strong market uptake thus far. 2Q sales should exce
